Superbugs thrive as access to antibiotics fails in India

It’s a gloomy paradox, doctors say.

On the one hand, antibiotics excessively, while they are not already working, lead to resistance and nourish the rise of deadly superbugians. On the other hand, people die because they do not have access to these life -saving drugs.

A new study of the partnership for global antibiotic studies and non-profit development (GARDP) examined access to antibiotics for nearly 1.5 million cases of carbapene resistant Gram-negative (CRGN) infections in eight major countries with medium and medium incomes, including India, Brazil and South Africa. CRGN bacteria are superbugy resistant to the last line antibiotics – but only 6.9% of patients have received appropriate treatment in the countries studied.

India carries the lion’s share of CRGN infections and efforts to treat, providing 80% of full courses of antibiotics studied, but managed to treat only 7.8% of its estimates, The exploration In Lancet infectious disease reports. (A complete course of antibiotic drugs refers to the complete set of doses that the patient should take a certain period to treat completely infection.)

Common in water, food, environment and human intestines, gram-negative bacteria cause infections such as urinary tract infections (UTI), pneumonia and food poisoning.

They can pose a serious threat to newborns and the elderly. Particularly vulnerable are hospital patients with weakened immunity, often spread quickly to ICU and are difficult – and sometimes impossible – for treatment. The treatment of carbapem resistant gram-negative bacterial infections is double as these bacteria are resistant to some of the most powerful antibiotics.

“These infections are a daily reality in all age groups,” says Dr. Abdul Gafar, a consultant on infectious diseases in Apollo Hospital in India in Chennai. “We often see patients for whom there is no antibiotic – and they die.”

The irony is cruel. While the world is trying to limit antibiotics of antibiotics, parallel tragedy plays quietly in the greater nations: people who die from treatable infections because the right drugs are out of reach.

“For years, the dominant story is that antibiotics are excessive, but the great reality is that many people with highly resistant drug infections in countries with low and average incomes do not get access to the antibiotics they need,” says Dr. Jennifer Kon, a global GARDP and senior author.

The study examined eight intravenous drugs active against carbapem resistant bacteria-boiling from older antibiotics, including Colistin to newer ones as Ceftazidim-Avibam. Of the few medicines available, Tigecycline was the most widely used.

Researchers blame the difference in the treatment of weak health systems and restricted access to effective antibiotics.

For example, only 103,647 full treatment courses were purchased from thigecycline in eight countries – far from 1.5 million patients who need them, the study found. This emphasized a major deficiency of the global response to drug resistant infections.

What prevents patients with drug resistant infections in India from getting the right antibiotics?

Doctors point to multiple barriers – reaching the right healthcare facility, obtaining accurate diagnostic tests and access to effective medicines. The price remains a major obstacle, with many of these antibiotics priced far beyond the reach of the greater patients.

“Those who can afford these antibiotics often overdo them; “We need a system that guarantees access to the poor and prevents abuse of well.”

In order to improve access, these drugs must be more accessible. To prevent abuse, more severe regulation is crucial.

“Ideally, any recipe for antibiotics in hospitals should require a second write -off – from an infection specialist or microbiologist,” says Dr. Gafar. “Some hospitals do this, but most do not. With the right supervision, regulators can ensure that this becomes a standard practice.”

To eliminate the problem of access and to limit abuse, both intelligent policies and stronger precautions are essential, researchers say. But access in itself will not resolve the crisis – the pipeline of new antibiotics dries. The decline in antibiotic research and development – and the limited availability of existing drugs – is a global problem.

India bears One of the most severe weights in the world of antimicrobial resistance (AMR), but it can also keep the key to fighting it – both at home and globally, the researchers say.

“India is also one of the biggest markets for new antibiotics and can successfully stand up for the development and access of new antibiotics,” says Dr. With a strong pharmaceutical base, the country emerges as an AMR innovation center, from Promising new antibiotics to advanced diagnostics.

D -C KON says that India can enhance its antibiotic response by generating local data to better evaluate the needs and determine the gaps in the care path.

This would allow more targeted interventions to improve access to the right medicines.

Innovative models are already emerging as Kerala, for example, uses a “hub approach and spokes” to maintain lower levels when managing serious infections. Coordinated or combined orders in hospitals or countries can also reduce the cost of more antibiotics, as seen in drug cancer programs, researchers say.

Without access to the right antibiotics, modern medicine begins to unravel – doctors risk losing the ability to perform a safe surgery, treat complications in patients with cancer, or manage daily infections.

“As an infectious disease doctor, I see appropriate use as one part – but only one part – for access,” says Dr. Gafar. “When we get new antibiotics, it is important to save them on the one hand – to save them for the right patients.”

It is clear that the challenge is not simply to use reasonably antibiotics, but also to ensure that they reach those who need the most of them.